Stock comparison
Corcept Therapeutics
Haemonetics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CORT
Corcept Therapeutics
Market cap
$6.34B
Sector
Healthcare
HAE
Haemonetics
Market cap
$2.77B
Sector
Healthcare
Overall winner
Corcept Therapeutics CORT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CORT | HAE | Winner |
|---|---|---|---|
| Warren Buffett | 68D | 70B | HAE |
| Benjamin Graham | 86C | 85A | CORT |
| Philip Fisher | 64C | 60C | CORT |
| Peter Lynch | 32F | 54C | HAE |
| Joel Greenblatt | 47D | 31F | CORT |
| Charlie Munger | 60C | 54D | CORT |
| Terry Smith | 68C | 55D | CORT |
Side-by-side metrics
| Metric | CORT | HAE |
|---|---|---|
| Market cap | $6.34B | $2.77B |
| P/E (TTM) | 122.0x | 24.8x |
| EV/EBIT | 131.9x | 14.1x |
| ROIC (TTM) | -1.23% | 8.37% |
| Gross margin | 98.25% | 55.74% |
| Net margin | 6.23% | 7.29% |
| Revenue CAGR 5y | 20.1% | 7.65% |
| EPS CAGR 5y | -0.52% | 24.62% |
| Debt / Equity | 0.0x | 1.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CORT leads on
- Debt / Equity0.0xvs 1.5x+99%
- Revenue CAGR 5y20.1%vs 7.65%+62%
- Market cap$6.34Bvs $2.77B+56%
- Gross margin98.25%vs 55.74%+43%
HAE leads on
- ROIC (TTM)8.37%vs -1.23%+115%
- EPS CAGR 5y24.62%vs -0.52%+102%
- EV/EBIT14.1xvs 131.9x+89%
- P/E (TTM)24.8xvs 122.0x+80%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.